{
  "name": "Vaccine vector examples: replication, antigen and source scope",
  "description": "Original cross-source compilation of three vaccine-vector examples. EMA descriptions of host restriction and gene deletion are combined with WHO vaccine-mechanism explanations and CDC product information. These are biological classifications, not an availability list or a ranking of safety or efficacy.",
  "page": "https://casrai.org/guides/viral-vector-vaccine",
  "publisher": "CASRAI",
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "dateModified": "2026-11-15T03:39:57Z",
  "temporalCoverage": null,
  "spatialCoverage": null,
  "columns": [
    {
      "name": "Vector example",
      "unit": "",
      "description": ""
    },
    {
      "name": "Replication in human recipient cells",
      "unit": "",
      "description": ""
    },
    {
      "name": "Antigen or delivery distinction",
      "unit": "",
      "description": ""
    },
    {
      "name": "Source and scope",
      "unit": "",
      "description": ""
    }
  ],
  "rows": [
    {
      "Vector example": "Engineered adenovirus vaccine vectors with replication-gene deletions",
      "Replication in human recipient cells": "Replication-defective",
      "Antigen or delivery distinction": "Can enter cells and express the encoded target antigen without producing new vector virus.",
      "Source and scope": "EMA guideline section 2; WHO Update 73 viral vector mechanism. Describes engineered vaccine vectors, not all adenoviruses."
    },
    {
      "Vector example": "Avipox vectors and modified vaccinia Ankara (MVA)",
      "Replication in human recipient cells": "Replication restricted in humans",
      "Antigen or delivery distinction": "Avipox host restriction and MVA attenuation through passage are distinct routes to replication deficiency.",
      "Source and scope": "EMA guideline section 2. These are vaccine-vector examples rather than a statement that all poxviruses share this property."
    },
    {
      "Vector example": "ERVEBO recombinant vesicular stomatitis virus (VSV)",
      "Replication in human recipient cells": "Replication-competent; live and attenuated",
      "Antigen or delivery distinction": "VSV carrier containing a gene from Ebola virus; does not contain whole Ebola virus.",
      "Source and scope": "CDC Ebola Vaccine Product Information. Product-specific example targeting Zaire ebolavirus."
    }
  ],
  "sources": [
    {
      "title": "EMA guideline on live recombinant viral vectored vaccines (TGA-hosted copy)",
      "url": "https://www.tga.gov.au/sites/default/files/2024-12/guideline_on_clinical_and_clinical_aspects_of_live_recombinant_viral_vectored_vaccines.pdf",
      "accessed": "2026-11-15"
    },
    {
      "title": "WHO COVID-19 vaccines and immune response, Update 73",
      "url": "https://www.who.int/docs/default-source/coronaviruse/risk-comms-updates/update73_covid-19-vaccines-and-immune-response.pdf",
      "accessed": "2026-11-15"
    },
    {
      "title": "CDC Ebola Vaccine Product Information",
      "url": "https://www.cdc.gov/ebola/hcp/vaccines/",
      "accessed": "2026-11-15"
    }
  ]
}